Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Paying For Cures Requires Bigger Budgets, Not Lower Drug Prices – Execs

Executive Summary

Payors need to adopt a longer-term focus on coverage policies for prescription drugs and biologics that recognizes the benefits of covering high-priced, but often curative, treatments like those for hepatitis C, panelists argue at AEI-sponsored event.

Advertisement

Related Content

Medicare Part D Cost Trends: A Good News/Bad News Story For Biopharma
Time Is Now For Shaping CMS Drug Affordability, Innovation Policies – Slavitt
Amortized Payments For High-Cost Drugs Won't Work, Insurer CEOs Say
The Sovaldi Anniversary? Burgess Wants Part D Milestone To Change How Gov’t Values Rx Spending

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel